November 2021 – Lung Cancer

Looking at Lung Cancer without Stigma
Lung CancerIssue Introductions
In her introduction to this special issue on Lung Cancer, Lillie emphasizes that we need to inspire and help people to stop smoking, and get rid of the overall stigma surrounding this disease.
Becoming a Patient Advocate After a Small-Cell Lung Cancer Diagnosis at Age 28
Patient StoriesLung CancerPatient Advocacy
Montessa Lee’s pain persisted after an initial visit to the doctor and a misdiagnosis. Finally, an x-ray in the emergency room revealed a 15-cm mass on her left lung. Read how she turned anger into action.
Immunotherapy Beneficial in Patients with Early-Stage Non–Small-Cell Lung Cancer and PD-L1 Expression
Lung CancerImmunotherapyBiomarkers
For the first time, the use of immunotherapy after surgical removal of the tumor and chemotherapy has shown benefits in patients with early-stage non–small-cell lung cancer (NSCLC) and PD-L1 expression, a biomarker found in some patients with NSCLC.
Tecentriq First Immunotherapy Approved for Adjuvant Treatment of Patients with Early-Stage NSCLC and PD-L1 Expression
FDA Approvals, News & UpdatesLung Cancer
On October 15, 2021, the FDA approved a new indication for Tecentriq (atezolizumab) for adjuvant (additional) treatment of patients with stage II-IIIA non–small-cell lung cancer and PD-L1 expression, after surgical removal of the tumor and chemotherapy. This is the first immunotherapy approved for patients with early-stage lung cancer.
The Pandemic Is Not Over: Staying Connected and Receiving Encouragement While Living with Lung Cancer
Patient StoriesLung Cancer
On his lonely journey dealing with lung cancer, Ron Simmons found that connecting with others who had lung cancer helped him create a sense of purpose and gave him a mission moving forward.
Exkivity Second FDA-Approved Oral Targeted Therapy for Patients with Metastatic NSCLC and EGFR Exon 20 Insertion Mutations
FDA Approvals, News & UpdatesLung CancerTargeted Therapies
On September 15, 2021, the FDA approved Exkivity (mobocertinib) capsules, an oral kinase inhibitor, for the treatment of adults with locally advanced or metastatic non–small-cell lung cancer (NSCLC) and EGFR exon 20 insertion mutations whose disease progressed during or after platinum-based chemotherapy, a cancer with few treatment options.
Clinical Trial Aims to Reduce Malnutrition in Patients with Lung Cancer
Nutrition & CancerLung CancerClinical Trials
Combating malnutrition should be at the forefront of cancer care, as studies have shown that up to 80% of patients with cancer are malnourished at some point during their treatment. Dr. Spees describes a new clinical trial focused on improving the nutrition of patients with lung cancer.
Advances in the Treatment of Patients with NSCLC and Genetic Mutations or with Small-Cell Lung Cancer
Lung CancerGenetics & Cancer
Although most of the drugs being developed for lung cancer these days are for non–small-cell lung cancer (NSCLC), there may be a shift on the horizon as new treatment options emerge for patients with small-cell lung cancer.
Getting the Most Out of Your Treatment: Your Role in Achieving Desired Outcomes in the Patient Journey
Multiple Myeloma
Nurse practitioner Beth Faiman, PhD, MSN, an expert in multiple myeloma, briefly discusses the unique features of this uncurable but very treatable cancer, highlighting that getting what you want out of treatment requires arming yourself with knowledge about the disease, evaluating your treatment goals, familiarizing yourself with your treatment team, and becoming an active participant in your treatment.
New Study Shows Causes of Lung Cancer in People Who Never Smoked
Lung CancerGenetics & CancerBiomarkers
It has become increasingly clear that lung cancer can be caused by different factors, including some environmental chemicals. Lung cancer in never smokers under the microscope.
Page 1 of 2
Results 1 - 10 of 11

Subscribe to CONQUER: the journey informed

Receive timely cancer news & updates, patient stories, and more.

Race or Ethnicity
Profession or Role
Primary Interest
Other Interests